FDA's Rare Disease Pilot Program Boosts Agency-Sponsor Communications and Therapy Development

The FDA has announced a new pilot program aimed at improving communication between sponsors working on rare disease treatments and the agency. The program will select participants based on their readiness to move forward with development programs, with up to three participants for each center.